Lipids in Health and Disease最新文献

{"title":"Phase 1 study of AYP-101 (soybean phosphatidylcholine): safety, pharmacokinetics, and lipid profile effects for reducing submental fat.","authors":"Hyun Joon Lee, Xu Jiang, A M Abd El-Aty, Ji Hoon Jeong, Jae-Yong Chung","doi":"10.1186/s12944-024-02387-4","DOIUrl":"10.1186/s12944-024-02387-4","url":null,"abstract":"<p><strong>Background: </strong>Excessive submental fat under the chin is a known aesthetic concern because of its negative impact on facial appearance and psychological well-being. AYP-101 is a newly developed injectable agent containing 93% soybean phosphatidylcholine (SPC) designed to reduce submental fat. We conducted a phase 1 study to evaluate the safety, pharmacokinetic (PK), and lipid profile effects of AYP-101.</p><p><strong>Methods: </strong>This study was a randomized, double-blind, placebo-controlled, single-dose, two-cohort trial. Participants were randomized into groups receiving 250 mg of AYP-101, 500 mg of AYP-101, or placebo at a 9:9:8 ratio across both cohorts. Safety was assessed through standard clinical evaluations. Blood samples were collected up to 144 h postdose in cohort 1 and up to 48 h postdose in cohort 2. The PK parameters were calculated via noncompartmental analysis.</p><p><strong>Results: </strong>All 26 randomized subjects completed the study. A total of 72 solicited adverse drug reactions (ADRs) were reported by 24 subjects, all of which were mild. The most common ADRs were injection site pain and bruising. There were 29 ADR cases in the 250 mg group; 26 cases in the 500 mg group; and 18 cases in the placebo group, indicating that there were no clinically significant differences in the safety profiles between the groups. All the dose groups presented similar PK profiles, with C_max values of 12.86, 13.44, and 13.61 µg/L and AUC_0-24 h values of 278.06, 274.79, and 267.63 µg*h/L, respectively. No clinically significant differences in PK or lipid profiles were observed between the postdose group and the baseline group for any of the dose groups.</p><p><strong>Conclusions: </strong>AYP-101 appears to be a safe candidate for treating submental fat, with localized reactions and no systemic exposure at single subcutaneous doses of up to 500 mg.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT05476094.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"426"},"PeriodicalIF":3.9,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Familial hypercholesterolemia in Chinese children and adolescents: a multicenter study.","authors":"Meng-Na Huang, Chen-Cen Wang, Ming-Sheng Ma, Mei-Zhu Chi, Qing Zhou, Li-Hong Jiang, Chun-Lin Wang, Mei Lu, Xiao-Quan Chen, Ya-Ying Cheng, Qing Ke, Da-Yan Wang, Xiao-Xia Qian, Xiao-Ming Ying, Jian-Ping Zhang, Qun-Hua Shen, Li-Fang Liu, Rui Gu, Zhen-Jie Zhang, Jian-Hua Feng, Min Wang, Ming-Qiang Zhu, Ke Huang, Jun-Fen Fu, Chao-Chun Zou","doi":"10.1186/s12944-024-02406-4","DOIUrl":"10.1186/s12944-024-02406-4","url":null,"abstract":"<p><strong>Background: </strong>Familial hypercholesterolemia (FH) is an inherited disorder mainly marked by increased low-density lipoprotein cholesterol (LDL-C) concentrations and a heightened risk of early-onset arteriosclerotic cardiovascular disease (ASCVD). This study seeks to characterize the genetic spectrum and genotype‒phenotype correlations of FH in Chinese pediatric individuals.</p><p><strong>Methods: </strong>Data were gathered from individuals diagnosed with FH either clinically or genetically at multiple hospitals across mainland China from January 2016 to June 2024.</p><p><strong>Results: </strong>In total, 140 children and adolescents (mean age of 6.00 years) with clinically and genetically diagnosed FH were enrolled in the study, with 87 distinct variants identified in the LDLR, APOB and PCSK9 genes. Among the variants, 11 variants were newly identified worldwide, with 9 classified as \"pathogenic\" or \"likely pathogenic\", and 2 classified as \"variants of uncertain significance\". Additionally, the 5 most common variants in the study were c.1448G > A (p.W483*), c.1879G > A (p.A627T), c.1216C > A (p.R406R), and c.1747C > T (p.H583Y) in the LDLR gene, as well as c.10579C > T (p.R3527W) in the APOB gene, accounting for 49.29% (69/140) of all patients. These variants are primarily observed in the Asian or Chinese population and are distinct from those present in Caucasian groups. In this cohort, 105 patients were diagnosed with heterozygous FH (HeFH), while 35 were diagnosed with homozygous FH (HoFH). Finally, only 28.57% of the patients (40/140) were using lipid-lowering medications with 33.33% of HoFH patients initiating treatment after the age of 8. Additionally, only 3 compound heterozygous patients (2.14%) underwent liver transplantation because of significantly high lipid levels.</p><p><strong>Conclusion: </strong>This study reveals the variable genotypes and phenotypes of children with FH in China and illustrates that the genotypes in the Chinese population differ from those in Caucasians, providing a valuable dataset for the clinical genetic screening of FH in China. Furthermore, the older age at diagnosis and treatment highlights the underdiagnosis and undertreatment of Chinese FH pediatric patients, suggesting that early identification should be improved through lipid or genetic screening, and that more timely and regular pharmacological treatments should be implemented.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"423"},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the EHBP1 SNPs and dyslipidemia in the end-stage renal disease patients with dialysis in Chinese Han population.","authors":"Yan-Fei Lai, Zhong-E Liang, Chun-Xiang Wu, Min Zhang, Zong-Hu Shi, Xiao-Yan Meng, Chun-Xiao Liu","doi":"10.1186/s12944-024-02407-3","DOIUrl":"10.1186/s12944-024-02407-3","url":null,"abstract":"<p><strong>Background: </strong>Lipid metabolism is influenced by mutations in the EH domain binding protein 1 gene (EHBP1). This study investigated the link between the EHBP1 single-nucleotide polymorphisms (SNPs) and dyslipidemia risks in maintenance dialysis patients with end-stage renal disease in Chinese Han population.</p><p><strong>Methods: </strong>A total of 539 patients were divided into dyslipidemia (379) and control (160) groups. The patients with dyslipidemia were divided into four subgroups: high low-density lipoprotein cholesterol, low high-density lipoprotein cholesterol (HDLC), high triglyceride (TG) and high total cholesterol groups. The genotype distributions of three EHBP1 SNPs (rs2710642, rs10496099 and rs1168816) were determined by high-throughput sequencing technology and were analyzed via generalized multifactor dimension reduction and binary logistic regression analysis.</p><p><strong>Results: </strong>The high-TG and control groups differed in terms of the genotype frequency of the rs2710642. One haplotype was detected in both the dyslipidemia and high-TG groups. The risk of dyslipidemia was 2.72-fold higher in participants with rs2710642GG compared with those of rs2710642AA and 2.62-fold higher compared with those with rs2710642AA + GA. Subjects who carried rs2710642GG had a 2.94 times greater risk of high TG levels than those who carried rs2710642AA and a 2.89 times greater risk than those who carried rs2710642AA + GA. Compared with those who carried rs2710642AA + GA, those who carried rs2710642GG were 2.53 times more likely to have low HDLC levels. The rs2710642-body mass index (BMI) (≥ 24 kg/m²) and rs11688816A-rs2710642G haplotype interactions increased the risk of dyslipidemia, and the rs2710642-BMI (≥ 24 kg/m²) interaction increased the risk of high TG levels. The rs10496099-rs2710642 and rs10496099-rs2710642-rs11688816 interactions increased the risk of low HDLC levels.</p><p><strong>Conclusions: </strong>These results suggest that the EHBP1 rs2710642G and rs2710642GG and interactions with rs11688816A or BMI (≥ 24 kg/m²) were linked to higher dyslipidemia risks in end-stage renal disease patients in Chinese Han population.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"422"},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between cardiometabolic index and all-cause and cause-specific mortality among the general population: NHANES 1999-2018.","authors":"Mingjie Liu, Chendong Wang, Rundong Liu, Yan Wang, Bai Wei","doi":"10.1186/s12944-024-02408-2","DOIUrl":"10.1186/s12944-024-02408-2","url":null,"abstract":"<p><strong>Background: </strong>Cardiometabolic index (CMI) is a comprehensive clinical parameter which integrates overweight and abnormal lipid metabolism. However, its relationship with all-cause, cardiovascular disease (CVD), and cancer mortality is still obscure. Thus, a large-scale cohort study was conducted to illustrate the causal relation between CMI and CVD, cancer, and all-cause mortality among the common American population.</p><p><strong>Methods: </strong>Our research was performed on the basis of National Health and Nutrition Examination Survey (NHANES) database, involving 40,275 participants ranging from 1999 to 2018. The formula of CMI is [waist circumference (cm) / height (cm)] × [triglyceride (mg/dL) / high-density lipoprotein cholesterol (mg/dL)]. Outcome variables consisted of CVD, cancer, and all-cause mortality, which were identified by the International Classification of Diseases (ICD)-10. The correlation between CMI and mortality outcomes was analyzed utilizing the Kaplan-Meier survival modeling, univariate/multivariate Cox regression analysis, smooth curve fitting analysis, threshold effect analysis, and subgroup analysis. Stratification factors for subgroups included age, race/ethnicity, sex, smoking behavior, drinking behavior, BMI, hypertension, and diabetes.</p><p><strong>Results: </strong>The baseline characteristics table includes 4,569 all-cause-induced death cases, 1,113 CVD-induced death cases, and 1,066 cancer-induced death cases. Without adjustment for potential covariates, significantly positive causal correlation existed between CMI and all-cause mortality (HR = 1.03, 95% CI 1.02,1.04, P-value<0.05), CVD mortality (HR = 1.04, 95% CI 1.03, 1.05, P-value<0.05) and cancer mortality(HR = 1.03, 95% CI 1.02, 1.05, P-value<0.05); whereas, after confounding factors were completely adjusted, the relationship lost statistical significance in CMI subgroups (P for trend>0.05). Subgroup analysis found no specific subgroups. Under a fully adjusted model, a threshold effect analysis was performed combined with smooth curve fitting, and the findings suggested an L-shaped nonlinear association within CMI and all-cause mortality (the Inflection point was 0.98); in particular, when the baseline CMI was below 0.98, there existed a negative correlation with all-cause mortality with significance (HR 0.59, 95% CI 0.43, 0.82, P-value<0.05). A nonlinear relation was observed between CMI and CVD mortality. Whereas, the correlation between CMI and cancer mortality was linear.</p><p><strong>Conclusions: </strong>Among the general American population, baseline CMI levels exhibited an L-shaped nonlinear relationship with all-cause mortality, and the threshold value was 0.98. What's more, CMI may become an effective indicator for CVD, cancer, and all-cause mortality prediction. Further investigation is essential to confirm our findings.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"425"},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knockdown of RASD1 improves MASLD progression by inhibiting the PI3K/AKT/mTOR pathway.","authors":"Guifang Zeng, Xialei Liu, Zhouying Zheng, Jiali Zhao, Wenfeng Zhuo, Zirui Bai, En Lin, Shanglin Cai, Chaonong Cai, Peiping Li, Baojia Zou, Jian Li","doi":"10.1186/s12944-024-02419-z","DOIUrl":"10.1186/s12944-024-02419-z","url":null,"abstract":"<p><strong>Background: </strong>There is still no reliable therapeutic targets and effective pharmacotherapy for metabolic dysfunction-associated steatotic liver disease (MASLD). RASD1 is short for Ras-related dexamethasone-induced 1, a pivotal factor in various metabolism processes of Human. However, the role of RASD1 remains poorly illustrated in MASLD. Therefore, we designed a study to elucidate how RASD1 could impact on MASLD as well as the mechanisms involved.</p><p><strong>Methods: </strong>The expression level of RASD1 was validated in MASLD. Lipid metabolism and its underlying mechanism were investigated in hepatocytes and mice with either overexpression or knockdown of RASD1.</p><p><strong>Results: </strong>Hepatic RASD1 expression was upregulated in MASLD. Lipid deposition was significantly reduced in RASD1-knockdown hepatocytes and mice, accompanied by a marked downregulation of key genes in the signaling pathway of de novo lipogenesis. Conversely, RASD1 overexpression in hepatocytes had the opposite effect. Mechanistically, RASD1 regulated lipid metabolism in MASLD through the PI3K/AKT/mTOR signaling pathway.</p><p><strong>Conclusions: </strong>We discovered a novel role of RASD1 in MASLD by regulating lipogenesis via the PI3K/AKT/mTOR pathway, thereby identifying a potential treatment target for MASLD.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"424"},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Low‑grade inflammation is associated with a heterogeneous lipoprotein subclass profile in an apparently healthy population sample.","authors":"Daniel L Pontzen, Martin Bahls, Diana Albrecht, Stephan B Felix, Marcus Dörr, Till Ittermann, Matthias Nauck, Nele Friedrich","doi":"10.1186/s12944-024-02413-5","DOIUrl":"10.1186/s12944-024-02413-5","url":null,"abstract":"","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"420"},"PeriodicalIF":3.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracking of serum lipids from prepuberty to young adulthood: results from the KiGGS cohort study.","authors":"Julia Truthmann, Anja Schienkiewitz, Antje Kneuer, Yong Du, Christa Scheidt-Nave","doi":"10.1186/s12944-024-02409-1","DOIUrl":"10.1186/s12944-024-02409-1","url":null,"abstract":"<p><strong>Background: </strong>Universal lipid screening in childhood for early detection and treatment of familial hypercholesterolemia is under discussion, but will also detect children with multifactorial dyslipidemia. Results from population-based studies can support the design of public health strategies. As few previous studies considered pubertal changes in serum lipid levels, we examined tracking of serum lipids from prepuberty to young adulthood in a population-based cohort.</p><p><strong>Methods: </strong>This longitudinal study includes 692 children from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS; baseline: 2003-2006, follow-up: 2014-2017) who were 6-8 years old at baseline, at least 18 years old at follow-up, and had measurements of serum total cholesterol (TC), high-density and non-high-density lipoprotein cholesterol (HDL-C; non-HDL-C) at both time points. We calculated proportions of participants by life stage-specific risk categories applying cut points for young children and young adults. We used correlation coefficients to estimate serum lipid tracking from childhood to young adulthood. The association between follow-up and baseline lipid levels was examined in sex-specific multivariable linear regression models including body mass index (BMI), health-related behaviors and medication use as covariables.</p><p><strong>Results: </strong>The correlation coefficient between baseline and follow-up was 0.60 for non-HDL-C, 0.56 for TC, and 0.43 for HDL-C and was higher in males than in females. 67% of participants had acceptable and 9% had borderline/elevated non-HDL-C levels at both time points. Of participants with borderline/elevated non-HDL-C levels at baseline 32% remained in this category and 68% improved. Non-HDL-C levels at baseline explained 53% of the variance in levels at follow-up in males and 28% in females. After adjustment for covariables, the explained variance increased to 62% in males and 45% in females. An increase in BMI z-scores from childhood to young adulthood in all sexes and oral contraceptive use in females was positively associated with higher levels at follow-up.</p><p><strong>Conclusions: </strong>Non-HDL-C levels in prepuberty are moderate predictors of levels in young adulthood, along with increasing BMI from childhood to young adulthood, and oral contraceptive use among women. Comprehensive strategies including public health interventions targeting elevated lipid levels and obesity in combination, are essential to prevent premature cardiovascular events.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"421"},"PeriodicalIF":3.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between triglyceride-glucose index and its correlation indexes and stress urinary incontinence in postmenopausal women: evidence from NHANES 2005-2018.","authors":"Xueping Huang, Wen Hu, Limei Li","doi":"10.1186/s12944-024-02414-4","DOIUrl":"10.1186/s12944-024-02414-4","url":null,"abstract":"<p><strong>Background: </strong>Postmenopausal women are more susceptible to stress urinary incontinence (SUI), and insulin resistance (IR) is closely related to SUI. The triglyceride-glucose (TyG) index is an efficient metric for assessing IR. Investigating whether TyG index and its correlation indexes were correlated with SUI in postmenopausal women was the aim of this research.</p><p><strong>Methods: </strong>Data from 2,132 postmenopausal women from the National Health and Nutrition Examination Survey (NHANES) were included in the study for analysis. Weighted multiple logistic regression was used to evaluate the correlation between the TyG index and its correlation indexes and SUI. The nonlinear correlation between the TyG correlation indexes and SUI, as well as the diagnostic efficacy for SUI, was investigated using the smooth curve approach and receiver operating characteristics. Through detailed subgroup analysis, the stability and generalization of the results are confirmed.</p><p><strong>Results: </strong>Of the 26.87 million, 13.63 million, or 50.73%, suffered from SUI. The prevalence of SUI was significantly higher in the fourth quartile of TyG-BMI (OR = 1.93, 95% CI 1.13-2.84), TyG-WC (OR = 1.76, 95% CI 1.23-2.51), and TyG-WHtR (OR = 1.81, 95% CI 1.28-2.55) compared to the first quartile. Among the three models, TyG-WHtR always maintained a more significant correlation with SUI (Model 1:OR = 1.30;Model 2:OR = 1.33; Model 3:OR = 1.24). Smooth curve fitting results showed that TyG correlation indexes were not linearly correlated with SUI (P > 0.05). Subgroup analysis further confirmed the reliability and applicability of the results. TyG-BMI had the greatest diagnostic performance for SUI out of the four markers.</p><p><strong>Conclusions: </strong>In comparison to TyG, TyG correlation indexes showed a more significant correlation with SUI among postmenopausal women in US, with TyG-BMI showing the best diagnostic effectiveness.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"419"},"PeriodicalIF":3.9,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of visceral adiposity index and lipid accumulation product with frailty in U.S. adults: a cross-sectional study from NHANES.","authors":"Shaohua Yan, Ke Chai, Jiefu Yang, Hua Wang","doi":"10.1186/s12944-024-02410-8","DOIUrl":"10.1186/s12944-024-02410-8","url":null,"abstract":"<p><strong>Background: </strong>Frailty poses a considerable public health challenge because of its association with negative health consequences. Although obesity is recognized as a contributor to frailty, conventional measures fail to adequately account for the effects of visceral adiposity. The study aimed to investigate the associations between the visceral adiposity index (VAI) or lipid accumulation product (LAP) and frailty.</p><p><strong>Methods: </strong>This study used data from the National Health and Nutrition Examination Survey (NHANES), which included 5,279 participants aged ≥ 20 years. The VAI and LAP were calculated via recognized formulas, and frailty was evaluated via a deficit accumulation approach. We employed logistic regression and restricted cubic splines to assess the associations among LAP, VAI and frailty.</p><p><strong>Results: </strong>Out of 5,279 participants, 1,836 individuals were categorized as frail. According to the fully adjusted models, the highest VAI and LAP values were significantly associated with frailty, with adjusted ORs of 1.84 (95% CI: 1.40-2.42) and 2.47 (95% CI: 1.89-3.24), respectively, compared with the lowest values. A nonlinear relationship was identified between the LAP and frailty, with an inflection point of 1.589 (ln-transformed), whereas the VAI was linearly associated with frailty. Sensitivity analyses confirmed the robustness of these associations.</p><p><strong>Conclusion: </strong>The VAI and LAP are significantly related to frailty, highlighting the importance of visceral adiposity in frailty risk. These results increase the understanding of the metabolic underpinnings of frailty and may guide the development of targeted prevention strategies.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"417"},"PeriodicalIF":3.9,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes.","authors":"Verena Gounden, Sridevi Devaraj, Ishwarlal Jialal","doi":"10.1186/s12944-024-02412-6","DOIUrl":"10.1186/s12944-024-02412-6","url":null,"abstract":"<p><strong>Background: </strong>The Triglyceride-glucose (TyG) index represents a simple, cost-effective, and valid proxy for insulin resistance. This surrogate marker has also been proposed as a predictor of metabolic and cardiovascular disease (CVD). In this descriptive review, we aimed to assess the utility of the TyG index as a predictive biomarker of cardiometabolic diseases.</p><p><strong>Methods: </strong>A search was conducted in PubMed, and Web of Science to identify cross-sectional and more importantly prospective studies examining the use of the TyG index as a predictive biomarker. The following terms were utilized in addition to the TyG index: \"insulin resistance\", \"metabolic syndrome\", \"diabetes\"; \"cardiovascular diseases\".</p><p><strong>Results: </strong>This descriptive review included thirty prospective studies in addition to cross-sectional studies. Following adjustment for confounding variables, an elevated TyG index was associated with a significantly increased risk for the development of Metabolic Syndrome (MetS), Type 2 Diabetes, hypertension, and CVD. Also in limited studies, the TyG index was associated with endothelial dysfunction, increased oxidative stress and a pro-inflammatory phenotype.</p><p><strong>Conclusion: </strong>Overall, our findings support the use of the TyG index as a valid biomarker to assess the risk of developing MetS, T2DM, as well as atherosclerotic cardiovascular disease.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"416"},"PeriodicalIF":3.9,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}